OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo- controlled trial in adult females

Jan 18

Written by Sebastian De Beurs

Sebastian De Beurs

Effects of botulinum toxin type a on mood and cognitive function in patients with parkinson’s disease and depression

Treatment of Major Depressive Disorder Using Botulinum Toxin A: A 24-Week Randomized, Double-Blind, Placebo-Controlled Study